Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors

Author:

Replogle Joseph M1234ORCID,Bonnar Jessica L234ORCID,Pogson Angela N234ORCID,Liem Christina R2ORCID,Maier Nolan K5ORCID,Ding Yufang5ORCID,Russell Baylee J5ORCID,Wang Xingren5,Leng Kun16,Guna Alina24,Norman Thomas M2,Pak Ryan A2,Ramos Daniel M78,Ward Michael E9ORCID,Gilbert Luke A21011ORCID,Kampmann Martin612ORCID,Weissman Jonathan S2341314ORCID,Jost Marco25ORCID

Affiliation:

1. Medical Scientist Training Program, University of California, San Francisco

2. Department of Cellular and Molecular Pharmacology, University of California, San Francisco

3. Howard Hughes Medical Institute, Massachusetts Institute of Technology

4. Whitehead Institute for Biomedical Research

5. Department of Microbiology, Harvard Medical School

6. Institute for Neurodegenerative Disease, University of California, San Francisco

7. Center for Alzheimer's Disease and Related Dementias, National Institutes of Health

8. National Institute on Aging, National Institutes of Health

9. National Institute of Neurological Disorders and Stroke, National Institutes of Health

10. Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

11. Arc Institute

12. Department of Biochemistry and Biophysics, University of California, San Francisco

13. Department of Biology, Massachusetts Institute of Technology

14. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Abstract

CRISPR interference (CRISPRi) enables programmable, reversible, and titratable repression of gene expression (knockdown) in mammalian cells. Initial CRISPRi-mediated genetic screens have showcased the potential to address basic questions in cell biology, genetics, and biotechnology, but wider deployment of CRISPRi screening has been constrained by the large size of single guide RNA (sgRNA) libraries and challenges in generating cell models with consistent CRISPRi-mediated knockdown. Here, we present next-generation CRISPRi sgRNA libraries and effector expression constructs that enable strong and consistent knockdown across mammalian cell models. First, we combine empirical sgRNA selection with a dual-sgRNA library design to generate an ultra-compact (1–3 elements per gene), highly active CRISPRi sgRNA library. Next, we compare CRISPRi effectors to show that the recently published Zim3-dCas9 provides an excellent balance between strong on-target knockdown and minimal non-specific effects on cell growth or the transcriptome. Finally, we engineer a suite of cell lines with stable expression of Zim3-dCas9 and robust on-target knockdown. Our results and publicly available reagents establish best practices for CRISPRi genetic screening.

Funder

National Institutes of Health

Springer Nature Global Grant for Gut Health

Charles H. Hood Foundation

Defense Advanced Research Projects Agency

Ludwig Center for Molecular Oncology

Chan Zuckerberg Initiative

Human Frontier Science Program

Howard Hughes Medical Institute

Pew Charitable Trusts

UCSF School of Medicine

Publisher

eLife Sciences Publications, Ltd

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3